SEC Filing | Graybug Vision, Inc.

View:

Download DOC

Download PDF

Download XLS

Download XBRL

10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-39538

CalciMedica, Inc.

(Exact name of Registrant as specified in its Charter)

Delaware

45-2120079

(State or other jurisdiction
of incorporation or organization)

(I.R.S. Employer
Identification No.)

505 Coast Boulevard South, Suite 307

La Jolla, CA 92037

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (858) 952-5500

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	CALC	The Nasdaq Capital Market

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The number of shares of the Registrant’s common stock outstanding as of August 4, 2023 was 5,661,933.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These forward-looking statements include, but are not limited to, statements concerning the following:

•

the success, cost and timing of our development activities, non-clinical studies and clinical trials;

•

the timing and outcome of our current and future clinical trials, and the reporting of data from those trials;

•

the potential of our technologies and our ability to execute on our corporate strategy;

•

our ability to attract and retain key scientific, medical, commercial and management personnel;

•

our ability to fund our working capital needs;

•

the strength and breadth of our patent portfolio;

•

the therapeutic potential of Auxora and our other product candidates;

•

the ability to obtain funding for our operations, including funding necessary to develop and commercialize our product candidates, subject to regulatory approvals:

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

our reliance on third parties to manufacture and conduct preclinical studies and clinical trials of our product candidates;

•

the success of competing therapies that are or may become available;

•

our ability to develop and maintain our corporate infrastructure, including our ability to design and maintain an effective system of internal controls;

•

existing regulations and regulatory developments in the United States and other regulations;

•

potential claims relating to our intellectual property;

•

our financial performance;

•

our ability to obtain and adequately protect intellectual property rights for our product candidates;

•

our ability to obtain regulatory approval for our product candidates and any related restrictions, limitations and/or warnings in the label of any approved product candidate;

•

our ability to extend our operating capital;

•

our ability to continue to satisfy the Nasdaq listing requirements and have our stock continue to trade on Nasdaq; and

•

the effects of the ongoing conflict between the Ukraine and Russia and the recent and potential future bank failures or other geopolitical events.

These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under the heading “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. You should not rely upon forward-looking statements as predictions of future events. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, after the date of this report, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

We obtained industry, market and competitive position data in this report from our own internal estimates and research as well as from industry and general publications and research surveys and studies conducted by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information or estimates.

EXPLANATORY NOTE

On March 20, 2023, the Delaware corporation formerly known as “Graybug Vision, Inc.” completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended on February 10, 2023 (the “Merger Agreement”), by and among Graybug Vision, Inc. (“Graybug”), Camaro Merger Sub, Inc., a wholly owned subsidiary of Graybug (“Merger Sub”), and CalciMedica, Inc. (“Private CalciMedica”), pursuant to which Merger Sub merged with and into Private CalciMedica, with Private CalciMedica surviving the merger as a wholly owned subsidiary of Graybug (the “Merger”). Additionally, on March 20, 2023, the Company changed its name from “Graybug Vision, Inc.” to “CalciMedica, Inc.” (the “Company”).

On March 17, 2023, in connection with the transactions contemplated by the Merger Agreement, Graybug filed an Amended and Restated Certificate of Incorporation effecting a reverse stock split of Graybug’s common stock at a ratio of 14:1 (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the number of issued and outstanding shares of Graybug’s common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 14 shares of Graybug’s common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of common stock after the Reverse Stock Split. The information in this Quarterly Report on Form 10-Q as of and for the periods prior to the effective date of the Merger gives effect to the Reverse Stock Split.

Since Private CalciMedica was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the condensed consolidated financial statements were prepared on a stand-alone basis for Private CalciMedica and did not include the combined entities’ activity or financial position. Subsequent to the Merger, the condensed consolidated financial statements as of and for the six months ended June 30, 2023 include Graybug’s activity from March 21, 2023 through June 30, 2023, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Private CalciMedica have been retroactively restated based on the exchange ratio of 0.0288.

In this Quarterly Report on Form 10-Q, unless the context indicates otherwise, the terms “Company,” “we,” “us,” and “our” refer to (i) Graybug Vision, Inc., for periods prior to the effectiveness of the Merger and (ii) CalciMedica, Inc. (as a combined company) for periods following the effectiveness of the Merger.

This report contains references to trademarks belonging to other entities, which are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Table of Contents


		Page
	PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	2
	Condensed Consolidated Balance Sheets	2
	Condensed Consolidated Statements of Operations and Comprehensive Loss	3
	Condensed Consolidated Statements of Stockholders’ Equity (Deficit)	4
	Condensed Consolidated Statements of Cash Flows	6
	Notes to the Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	29

	PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	30
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	75
Item 3.	Defaults Upon Senior Securities	75
Item 4.	Mine Safety Disclosures	75
Item 5.	Other Information	75
Item 6.	Exhibits	76
SIGNATURES		78

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

CALCIMEDICA, INC.

Condensed Consolidated Balance Sheets

(in thousands, except par value and share amounts)


	June 30, 2023			December 31, 2022
	(unaudited)			(See Note 2)
Assets
Current assets
Cash and cash equivalents	$	19,084		$	1,327
Restricted cash		—			149
Prepaid expenses and other current assets		961			254
Total current assets		20,045			1,730
Property and equipment, net		199			147
Right-of-use asset, net		—			48
Other assets		1			1,424
Total assets	$	20,245		$	3,349
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities
Accounts payable	$	1,743		$	2,866
Accrued clinical trial costs		1,207			1,143
Accrued other		1,074			572
Other current liabilities		—			199
Total current liabilities		4,024			4,780
Long-term liabilities
Warrant liability		—			2,645
Convertible promissory notes		—			5,157
Total liabilities		4,024			12,582
Commitments and contingencies (Note 8)
Convertible preferred stock
Series A convertible preferred stock, $0.001 par value; no shares and 25,751,716 authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			19,107
Series B convertible preferred stock, $0.001 par value; no shares and 11,235,460 authorized at June 30, 2023 and December 31, 2022, respectively; no shares and 10,667,279 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			8,224
Series C-1 convertible preferred stock, $0.001 par value; no shares and 8,016,886 shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			5,683
Series C-2 convertible preferred stock, $0.001 par value; no shares and 16,291,526 authorized at June 30, 2023 and December 31, 2022, respectively; no shares and 13,504,959 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			9,563
Series D convertible preferred stock, $0.001 par value; no shares and 88,875,077 authorized at June 30, 2023 and December 31, 2022, respectively; no shares and 26,880,040 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			19,494
Stockholders’ equity (deficit) (1)
Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized at June 30, 2023 and December 31, 2022, respectively; no shares issues issued and outstanding at June 30, 2023 and December 31, 2022, respectively		—			—
Common stock, $0.0001 par value; 500,000,000 and 5,694,626 shares authorized at June 30, 2023 and December 31, 2022, respectively; 5,661,933 and 84,165 issued and outstanding at June 30, 2023 and December 31, 2022, respectively		1			1
Additional paid-in capital		153,519			40,402
Accumulated deficit		(137,299	)		(111,707	)
Total stockholders’ equity (deficit)		16,221			(71,304	)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$	20,245		$	3,349

See accompanying notes to unaudited condensed consolidated financial statements.

(1) Retroactively restated for the reverse recapitalization as described in Note 2.

CALCIMEDICA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Operating expenses:
Research and development	$	3,814		$	2,259		$	10,305		$	5,184
General and administrative		2,769			1,330			18,618			2,616
Total operating expenses		6,583			3,589			28,923			7,800
Loss from operations		(6,583	)		(3,589	)		(28,923	)		(7,800	)
Other income (expense)
Other income (expense), net		279			(29	)		163			(29	)
Change in fair value of financial instruments		—			588			3,168			1,169
Total other income (expense), net		279			559			3,331			1,140
Net loss and comprehensive loss	$	(6,304	)	$	(3,030	)	$	(25,592	)	$	(6,660	)
Net loss per share—basic and diluted	$	(1.11	)	$	(36.55	)	$	(7.86	)	$	(82.42	)
Weighted-average number of shares outstanding used in computing net loss per share—basic and diluted		5,661,933			82,923			3,255,868			80,812

See accompanying notes to unaudited condensed consolidated financial statements.

CALCIMEDICA, INC.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

(Unaudited)


	Convertible Preferred Stock						Common Stock				Additional Paid-In			Accumulated			Total Stockholders’
	Shares			Amount			Shares		Amount		Capital			Deficit			Equity
Balance—December 31, 2022 (1)		84,820,880		$	62,071			84,165	$	1	$	40,402		$	(111,707	)	$	(71,304	)
Stock-based compensation expense								—		—		11,126			—			11,126
Conversion of preferred stock to common stock as a result of Merger		(84,820,880	)		(62,071	)		2,442,852		—		62,071			—			62,071
Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001		—			—			1,571,433		—		29,218			—			29,218
Issuance of common shares from private placement, net		—			—			596,363		—		10,340			—			10,340
Conversion of promissory notes into common stock		—			—			590,031		—		3,245			—			3,245
Conversion of Series C-2 Warrants into common stock		—			—			80,254		—		442			—			442
Conversion of promissory note warrants into common stock		—			—			152,875		—		841			—			841
Merger transaction costs		—			—			—		—		(4,591	)		—			(4,591	)
Restricted stock units net settlement		—			—			143,960		—		(297	)		—			(297	)
Reclassification of warrant liability to equity		—			—			—		—		216			—			216
Net loss		—			—			—		—		—			(19,288	)		(19,288	)
Balance—March 31, 2023		—			—			5,661,933		1		153,013			(130,995	)		22,019
Stock-based compensation expense		—			—			—		—		463			—			463
Adjustment to purchase accounting		—			—			—		—		3			—			3
Merger transaction costs		—			—			—		—		40			—			40
Net loss		—			—			—		—		—			(6,304	)		(6,304	)
Balance—June 30, 2023		—			—			5,661,933	$	1	$	153,519		$	(137,299	)	$	16,221

See accompanying notes to unaudited condensed consolidated financial statements.

(1) Retroactively restated for the reverse recapitalization as described in Note 2.

CALCIMEDICA, INC.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (1)

(in thousands, except share amounts)

(Unaudited)


	Convertible Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Accumulated Other Comprehensive		Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Income (Loss)		Equity
Balance—December 31, 2021		84,820,880		62,071		78,518	$	1	$	39,895	$	(103,883	)	$	—	$	(63,987	)
Stock issued on exercise of stock options		—		—		180		—		1		—			—		1
Stock-based compensation expense		—		—		—		—		335		—			—		335
Net loss		—		—		—		—		—		(3,630	)		—		(3,630	)
Balance—March 31, 2022		84,820,880		62,071		78,698		1		40,231		(107,513	)		—		(67,281	)
Stock issued on exercise of stock options		—		—		4,320		—		17		—			—		17
Stock-based compensation expense		—		—		—		—		321		—			—		321
Net loss		—		—		—		—		—		(3,030	)		—		(3,030	)
Balance—June 30, 2022		84,820,880		62,071		83,018	$	1	$	40,569	$	(110,543	)	$	—	$	(69,973	)

See accompanying notes to unaudited condensed consolidated financial statements.

(1) Retroactively restated for the reverse recapitalization as described in Note 2.

CALCIMEDICA, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)


	Six Months Ended June 30,
	2023			2022
Operating activities:
Net loss	$	(25,592	)	$	(6,660	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		11,589			656
Depreciation and amortization		27			26
Change in the fair value of warrant liability		(1,146	)		(1,169	)
Change in the fair value of convertible promissory notes		(2,022	)
Non-cash interest expense		110			—
Accretion of discount on short-term investment		(55	)		—
Changes in operating assets and liabilities:
Prepaid expenses and other current and non-current assets		1,548			7
Accounts payable		(20	)		701
Accrued expenses and other liabilities		(1,986	)		597
Net cash used in operating activities		(17,547	)		(5,842	)
Investing activities:
Purchases of property and equipment		(